Cantor Fitzgerald Reaffirms “Overweight” Rating for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They presently have a $155.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 14.60% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Rothschild & Co Redburn lowered their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Barclays decreased their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $157.93.

Gilead Sciences Price Performance

NASDAQ GILD opened at $135.25 on Wednesday. Gilead Sciences has a 12 month low of $108.46 and a 12 month high of $157.29. The stock has a market cap of $167.92 billion, a price-to-earnings ratio of 18.43 and a beta of 0.32. The company’s 50 day moving average is $129.58 and its two-hundred day moving average is $136.11. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.26) by $0.51. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.01 earnings per share. As a group, research analysts anticipate that Gilead Sciences will post -0.78 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,000 shares of company stock valued at $10,641,790 in the last 90 days. Insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

Several hedge funds have recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at $26,000. Wealth Preservation Advisors LLC lifted its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Wilkerson Advisory Group LLC lifted its position in Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 78 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, up 10.6% year over year and above the $7.4 billion consensus estimate. The company’s $6.75-per-share loss was narrower than analyst expectations of roughly $7.07–$7.26. Gilead Sciences Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Excluding Veklury, product sales increased 10% to $7.6 billion. Double-digit HIV growth, including continued momentum for PrEP and the emerging Yeztugo franchise, strengthens the company’s core growth outlook. Management raised its 2026 HIV growth expectation to 9%–10%. Gilead Raises HIV Growth Outlook
• Positive Sentiment: Gilead won a California Supreme Court ruling stating that drugmakers do not have a duty to develop potentially safer alternatives to medicines already considered safe. The decision reduces a significant product-liability risk. California Court Rules for Gilead
• Positive Sentiment: The company declared a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and a yield of approximately 2.4%. The dividend is payable September 29 to shareholders of record September 15.
• Neutral Sentiment: Gilead’s updated 2026 EPS outlook of a $0.65–$0.30 loss is better than the prior consensus estimate for a $0.79 loss. However, projected revenue of $30.1 billion–$30.4 billion is slightly below the $30.5 billion analyst forecast, tempering the guidance benefit.
• Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment and underscoring pressure from the product’s decline. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: The quarterly loss compares with $2.01 in EPS a year earlier as acquisition-related charges and elevated R&D spending weighed on profitability.
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $1.95 million under a pre-arranged Rule 10b5-1 plan. Because he retained more than 592,000 shares, the transaction is a limited negative signal rather than a major change in insider conviction. CEO Share Sale

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.